Guy De Backer1, Joost Besseling2, John Chapman3, G Kees Hovingh2, John J P Kastelein2, Kornelia Kotseva4, Kausik Ray5, Željko Reiner6, David Wood4, Dirk De Bacquer7. 1. Department of Public Health, Ghent University, Ghent, Belgium. Electronic address: guy.debacker@ugent.be. 2. Department of Vascular Medicine, Academic Medical Centre, Amsterdam, The Netherlands. 3. INSERM and University of Pierre and Marie Curie, Pitié-Salpétrière University Hospital, Paris, France. 4. Cardiovascular Medicine, International Centre for Circulatory Health, National Heart and Lung Institute, Imperial College London, United Kingdom. 5. St George's University of London, London, United Kingdom. 6. Department of Internal Medicine, University Hospital Center Zagreb, School of Medicine, University of Zagreb, Croatia. 7. Department of Public Health, Ghent University, Ghent, Belgium.
Abstract
BACKGROUND: Familial hypercholesterolaemia (FH) is a hereditary disorder predisposing to premature coronary heart disease (CHD) and is until now mainly diagnosed clinically on the basis of a classical phenotype. Its prevalence varies and is estimated around 1 in 200-500; in patients with established CHD the prevalence is less well documented. METHODS AND RESULTS: In EUROASPIRE IV data were collected in coronary patients from 24 European countries by means of a standardized interview, bioclinical examination and venous blood sampling. Potential FH was estimated using an adapted version of the Dutch Lipid Clinic Network Criteria. Among the 7044 patients eligible for analysis, the prevalence of potential FH was 8.3%; 7.5% in men and 11.1% in women. The prevalence was inversely related to age with a putative prevalence of 1:5 in those with CHD <50 yrs of age in both sexes. Even among women aged 70 the prevalence was 1:10. Irrespective of age and gender, prevalence differed substantially between European regions; potential FH patients were more likely to smoke, had higher triglycerides levels and their blood pressure was less well controlled. The use of cardioprotective drugs and the prevalences of diabetes, obesity and central obesity were similar. CONCLUSIONS: The prevalence of potential FH in coronary patients is high; the results underscore the need to promote identification of FH in CHD patients and to improve their risk factor profile.
BACKGROUND:Familial hypercholesterolaemia (FH) is a hereditary disorder predisposing to premature coronary heart disease (CHD) and is until now mainly diagnosed clinically on the basis of a classical phenotype. Its prevalence varies and is estimated around 1 in 200-500; in patients with established CHD the prevalence is less well documented. METHODS AND RESULTS: In EUROASPIRE IV data were collected in coronary patients from 24 European countries by means of a standardized interview, bioclinical examination and venous blood sampling. Potential FH was estimated using an adapted version of the Dutch Lipid Clinic Network Criteria. Among the 7044 patients eligible for analysis, the prevalence of potential FH was 8.3%; 7.5% in men and 11.1% in women. The prevalence was inversely related to age with a putative prevalence of 1:5 in those with CHD <50 yrs of age in both sexes. Even among women aged 70 the prevalence was 1:10. Irrespective of age and gender, prevalence differed substantially between European regions; potential FHpatients were more likely to smoke, had higher triglycerides levels and their blood pressure was less well controlled. The use of cardioprotective drugs and the prevalences of diabetes, obesity and central obesity were similar. CONCLUSIONS: The prevalence of potential FH in coronary patients is high; the results underscore the need to promote identification of FH in CHD patients and to improve their risk factor profile.
Authors: Zahid S Ahmad; Rolf L Andersen; Lars H Andersen; Emily C O'Brien; Iris Kindt; Peter Shrader; Chandna Vasandani; Connie B Newman; Emil M deGoma; Seth J Baum; Linda C Hemphill; Lisa C Hudgins; Catherine D Ahmed; Iftikhar J Kullo; Samuel S Gidding; Danielle Duffy; William Neal; Katherine Wilemon; Matthew T Roe; Daniel J Rader; Christie M Ballantyne; MacRae F Linton; P Barton Duell; Michael D Shapiro; Patrick M Moriarty; Joshua W Knowles Journal: J Clin Lipidol Date: 2016-08-06 Impact factor: 4.766
Authors: Paul Crosland; Ross Maconachie; Sara Buckner; Hugh McGuire; Steve E Humphries; Nadeem Qureshi Journal: Atherosclerosis Date: 2018-05-17 Impact factor: 5.162